COVID-19 : convalescent plasma as a potential therapy

To the Editor: SARS-CoV-2, the cause of COVID-19, has posed a significant threat to global health. No specific treatment or effective prophylaxis has been established, and care of severely ill patients is largely supportive, with poor outcomes in those requiring ICU admission. Experimental therapies include antiviral agents such as remdesivir, lopinavir/ritonavir and favipiravir, hydroxychloroquine/chloroquine, interleukin-6 inhibitors such as tocilizumab, siltuximab and sarilumab, and COVID-19 convalescent plasma (CCP).